FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Biological: ipilimumab
Drug: cyclophosphamide
Procedure: biopsy
Biological: aldesleukin
Other: immunohistochemistry staining method
Genetic: polymerase chain reaction
Other: immunoenzyme technique
Biological: therapeutic cytotoxic T lymphocytes

First Posted Date: 2009-03-30

Last Posted Date: 2017-04-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00871481

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Phase 2

Completed

Conditions: Intraocular Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Hairy Cell Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Childhood Diffuse Large Cell Lymphoma
Nodal Marginal Zone B-cell Lymphoma

Interventions: Biological: rituximab
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2009-03-23

Last Posted Date: 2018-01-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 63

Registration Number: NCT00867529

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Zanamivir or Oseltamivir
Drug: TCAD
Other: Open label treatment with TCAD

First Posted Date: 2009-03-23

Last Posted Date: 2013-08-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00867139

Locations: 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Chronic Myelogenous Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Myelodysplastic Syndromes

Interventions: Drug: treosulfan
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: methotrexate

First Posted Date: 2009-03-12

Last Posted Date: 2021-06-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 96

Registration Number: NCT00860574

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Radiation: Iodine I 131 Monoclonal Antibody BC8
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-03-12

Last Posted Date: 2020-04-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00860171

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Not Applicable

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2009-02-16

Last Posted Date: 2011-05-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 96

Registration Number: NCT00844441

Locations: 🇨🇭
Clinical Cancer Research Center at University Hospital Basel, Basel, Switzerland
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Myelodysplastic Syndrome With Isolated Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: clofarabine
Drug: cytarabine

First Posted Date: 2009-02-10

Last Posted Date: 2017-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00839982

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Phase 2

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Vorinostat

First Posted Date: 2009-02-10

Last Posted Date: 2017-05-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00839956

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Leukemia
Lymphoma

Interventions: Drug: lenalidomide
Biological: rituximab

First Posted Date: 2009-02-02

Last Posted Date: 2015-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00833534

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2008-11-24

Last Posted Date: 2023-02-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00796068

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy